Moreover, in patients with breast cancer, hepcidin expression is significantly upregulated in tissues and serum and there is evidence supporting the role of hepcidin in the development of the malignant phenotype and resistance to doxorubicin [20,21,22]. Here, HAMP is linked to breast carcinoma.